A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/44 (2006.01)
Patent
CA 2630900
A method for improving the cytotoxic effect of Ecteinascidin-743 (ET-743) or an analog thereof on a tumor cell population in a patient the method including administering to the patient, sequentially or simultaneously, a therapeutically effective combination of a composition including ET-743 and an amount of a composition including a PARP-I inhibitor effective to increase the cytotoxic effect of ET-743 on the tumor cell population. Anti-tumor compositions containing a therapeutically effective amount of ET-743 and an amount of a PARP-I inhibitor effective to increase the tumor cytotoxicity of the ET-743 are also presented.
L'invention porte sur une méthode d'amélioration de l'effet cytotoxique de l'Ecteinascidine-743 (ET-743) ou d'un de ses analogues sur une population de cellules tumorales d'un patient. Ladite méthode consiste à administrer au patient séquentiellement ou simultanément une combinaison à effet thérapeutique d'une composition comprenant: de l'ET-743, et une quantité d'une composition comprenant un inhibiteur du PARP-I accroissant l'effet cytotoxique de l'ET-743 sur une population de cellules tumorales. L'invention porte également sur des compositions anti-tumorales contenant une quantité à effet thérapeutique d'ET-743 et une quantité d'un inhibiteur du PARP-I accroissant l'effet cytotoxique de l'ET-743 sur des tumeurs.
Mandola Michael
Scotto Kathleen A.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Sociedad Unipersonal Pharma Mar S.a.
University Of Medicine And Dentistry Of New Jersey
LandOfFree
Use of parp-1 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of parp-1 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of parp-1 inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1450173